Omics-Based Clinical Trials Market
Report ID: SQMIG35H2659
Report ID: SQMIG35H2659
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35H2659 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
184
|Figures:
79
Global Omics-Based Clinical Trials Market size was valued at USD 8.70 Billion in 2024 and is poised to grow from USD 9.81 Billion in 2025 to USD 25.72 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).
The omics-based clinical trials market trends includes services for planning, executing and analyzing studies using genomics, proteomics, metabolomics and other technologies. The main driver behind this is the increasing need for precision medicine, which drives sponsors to stratify patients on molecular signatures rather than broad phenotypes. Previous trials have looked at a limited number of biomarkers. With the development of next generation sequencing in the 2010s, the depth of analysis has increased. This has allowed oncology trials such as the TRK inhibitor trial to enroll only patients with NTRK fusions. This shift has led to smaller sample sizes, faster timelines and higher success rates, making omics integration a boon for pharmaceutical companies. The second pillar driving market growth is regulatory incentives and reimbursement schemes aligned to favor biomarker-based evidence.
The FDA’s companion diagnostic pathways now provide accelerated approval for drugs found to be effective in specified patient groups, leading sponsors to develop multiplexed panels to screen hundreds of alterations in a single trial. A recent CAR-T study combined single-cell RNA sequencing with patient stratification, improving prediction and halving development timelines. The shorter time frames mean less money spent, which in turn attracts capital and encourages biotech companies to launch platform solutions that deliver omics pipelines to pharmaceutical partners, creating a cycle of data generation, insight and faster therapeutic entry.
How is AI-driven Automation Reshaping the Omics-based Clinical Trials Market?
Artificial intelligence is transforming the omics-based clinical trials market share by enabling faster and more accurate analysis of complex multi-omics datasets generated throughout the clinical research process. Machine learning algorithms can identify hidden biomarker patterns, predict patient responses to therapies, and optimize patient stratification, allowing sponsors to design more targeted and efficient trials. AI-driven platforms also automate data integration across genomics, transcriptomics, proteomics, and metabolomics, reducing manual processing time while improving analytical consistency. These capabilities enhance trial success rates by supporting better participant selection, adaptive trial designs, and real-time monitoring of treatment outcomes.
Beyond data analysis, AI is streamlining clinical trial operations through predictive analytics, automated workflow management, and intelligent decision support. Natural language processing and generative AI help extract insights from electronic health records, scientific literature, and clinical documentation, accelerating patient recruitment and regulatory submissions. AI-powered digital platforms further enable continuous monitoring of patient data, early detection of safety signals, and faster protocol adjustments, reducing operational costs and shortening development timelines. As pharmaceutical companies increasingly integrate AI with omics technologies, the combination is driving more personalized, efficient, and data-driven clinical trials while supporting the broader adoption of precision medicine.
Market snapshot - (2026-2033)
Global Market Size
USD 8.7 Billion
Largest Segment
Multi-Omics
Fastest Growth
Multi-Omics
Growth Rate
12.8% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global omics-based clinical trials market is segmented by omics type, service type, phase, application, technology, end user and region. Based on omics type, the market is segmented into genomics, proteomics, transcriptomics, metabolomics, epigenomics and multi-omics. Based on service type, the market is segmented into biomarker discovery, patient stratification, sample analysis, bioinformatics & data analysis, clinical trial management and others. Based on phase, the market is segmented into phase I, phase II, phase III and phase IV. Based on application, the market is segmented into oncology, neurology, cardiovascular disorders, infectious diseases, rare diseases and others. Based on technology, the market is segmented into next-generation sequencing (NGS), mass spectrometry, PCR technologies, microarrays and AI & bioinformatics platforms. Based on end user, the market is segmented into pharmaceutical companies, biotechnology companies, contract research organizations (CROs) and academic & research institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Genomics is a dominant segment, and offers the most comprehensive view of genetic variation that directly impacts trial eligibility and therapeutic targeting. It provides a foundational data layer that sponsors rely on for design and regulatory justification, identifying hereditary risk factors and driver mutations. The maturation of sequencing platforms, the decreasing cost per genome, and the strong validation in oncology and rare disease programs reinforce its preeminence in omics-based clinical trials.
However, its strong growth momentum is observed in the transcriptomics segment, which captures dynamic gene expression changes, revealing drug response and disease progression in real time. Emerging single cell technologies and their integration with AI models are increasing its application in therapeutic areas, driving its adoption and opening up new pathways for biomarker discovery in ongoing trials.
Mass spectrometry technology is a leader in the field providing quantitative protein and metabolite profiling which complements sequencing data and informs pharmacodynamic endpoints. The sensitivity and multiplexing capability allows detailed molecular phenotyping and the standardized workflows enhance reproducibility across multicenter studies. With enhanced instrumentation and data pipelines, the confidence of the sponsor increases, further cementing its vital role in precision trial monitoring.
Key high growth area is emerging in next generation sequencing segment as it provides high throughput, base level resolution for supporting almost all genomic and transcriptomic assays used in trial design. The system’s scalability supports parallel processing of large patient cohorts and the fast turnaround times enable adaptive trial models. However, improvements in chemistry and bioinformatics pipelines are lowering entry barriers and widening its appeal beyond oncology to metabolic and infectious disease investigations, thus speeding up market growth.
To get detailed segments analysis, Request a Free Sample Report
North America is the leader with a convergence of world-class research institutions, deep capital ecosystems and a regulatory framework that encourages innovative trial designs. The region has enormous genomic databases, sophisticated bioinformatics platforms and a spirit of collaboration between academia, biotech firms and big pharma. Strong patient recruitment networks and high prevalence of early-adopter healthcare providers further accelerate trial execution. These strengths together provide an environment where omics-driven insights can be rapidly translated into clinical development, cementing the region’s leadership in the global landscape.
Omics-based clinical trials market outlook in the United States is propelled by a dense concentration of leading biotech hubs, premier academic centers, and a venture capital community that fuels cutting‑edge research. The regulatory agency provides clear pathways for adaptive trial designs, while extensive electronic health record systems enable large‑scale patient enrollment. This ecosystem supports rapid integration of multi‑omics data into therapeutic development, sustaining the United States as a primary driver of global innovation.
Omics-based clinical trials market forecast in Canada benefits from a publicly funded health system that facilitates broad patient access and data sharing across provinces. Strong collaborative networks link universities, research institutes, and emerging biotech companies, fostering a supportive environment for omics integration. The regulatory landscape emphasizes scientific rigor while encouraging novel trial methodologies, allowing Canadian investigators to contribute valuable insights to multinational studies and reinforce the country’s role in the broader North American market.
Europe’s growth is driven by collaborative research projects, harmonised regulatory standards and a rich network of academic excellence across the member states. The availability of large biobanking resources and cross-borders data sharing platforms makes possible large and diverse patient cohorts in the region. In advanced economies strong pharmaceutical clusters attract investment and collaborations with niche biotech companies. Furthermore, policy environments that are geared toward precision medicine and patient‐centred approaches are fertile ground for omics‐driven trial designs, positioning Europe as a vibrant hub of growth and innovation.
Omics-based clinical trials market regional outlook in Germany is anchored by a robust pharmaceutical sector, world‑renowned research universities, and a well‑established network of clinical trial sites. The country’s emphasis on data protection and standardized protocols ensures high‑quality multi‑omics integration. Collaborative public‑private partnerships accelerate translational research, while a skilled workforce supports sophisticated analytical capabilities, reinforcing Germany’s dominant position within the European market.
Omics-based clinical trials market regional forecast in the United Kingdom is experiencing accelerated growth due to vibrant biotech clusters, progressive regulatory guidance, and substantial public research funding. The nation’s strong tradition of clinical trial excellence attracts multinational sponsors seeking diverse patient populations. Integrated health data infrastructures and a focus on precision health initiatives enable rapid incorporation of genomic, proteomic, and metabolomic insights into trial designs, driving the United Kingdom’s reputation as the fastest‑growing European market.
Omics-based clinical trials market analysis in France is emerging through strategic government incentives, expanding biotech ecosystems, and a commitment to collaborative research. Leading academic hospitals and research institutes provide access to rich patient cohorts and advanced analytical platforms. The regulatory environment encourages innovative trial methodologies, while growing investment in life‑science startups enhances the country’s capacity to integrate multi‑omics data, positioning France as an increasingly influential player in the European landscape.
Asia Pacific is taking the lead with fast economic growth, robust government support for precision medicine and a swelling pool of scientists. The region features large, genetically diverse populations, increasing the value of omics data and allowing for detailed clinical studies. Investment in world-class sequencing facilities and bioinformatics capabilities are leading to faster translation of multi-omics insights into therapeutic pipelines. The region is benefitting from a vibrant environment of collaborative networks linking academia, industry and healthcare providers, which is enhancing the region’s contribution to global omics-driven clinical research.
Omics-based clinical trials market penetration in Japan is propelled by a mature pharmaceutical industry, advanced genomic infrastructure, and a health system that facilitates extensive patient enrollment. Government initiatives prioritize precision health, encouraging integration of multi‑omics data into trial designs. Strong collaborations between leading universities and biotech firms enhance analytical expertise, positioning Japan as a key contributor to innovative clinical research across the Asia Pacific region.
Omics-based clinical trials industry in South Korea is driven by aggressive investment in biotechnology, cutting‑edge sequencing platforms, and a regulatory framework that supports adaptive trial designs. The nation’s emphasis on data integration and artificial intelligence augments the analysis of complex omics datasets, while a highly connected healthcare network enables efficient patient recruitment, reinforcing South Korea’s growing influence within the regional market.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Personalized Medicine Adoption
Technological Advances in Sequencing
High Cost of Omics Platforms
Data Privacy Regulations
Request Free Customization of this report to help us to meet your business objectives.
The competitive landscape of the omics in clinical trials market is characterized by collaborations between contract research organizations (CROs), genomics technology providers, pharmaceutical companies, and AI-driven analytics firms seeking to advance precision medicine. Market participants are expanding multi-omics capabilities through acquisitions, strategic partnerships, and cloud-based data integration platforms that improve biomarker discovery, patient stratification, and decentralized clinical trial management. Increasing investments in genomic sequencing, artificial intelligence, and companion diagnostics are further intensifying competition as organizations strive to accelerate drug development while improving trial efficiency and regulatory outcomes.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis, the market is propelled primarily by the surge in personalized‑medicine adoption, which enables precise patient stratification and faster trial timelines, while continual advances in sequencing technology serve as a second key driver by lowering costs and speeding data delivery; however, the high expense of omics platforms remains a notable restraint limiting broader uptake. North America stands out as the dominant region thanks to its robust research ecosystem, capital availability, and supportive regulatory landscape, and within the sector the Genomics segment leads the market, offering the most comprehensive molecular insight that underpins trial design and regulatory justification.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 8.7 Billion |
| Market size value in 2033 | USD 25.72 Billion |
| Growth Rate | 12.8% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Omics-Based Clinical Trials Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Omics-Based Clinical Trials Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Omics-Based Clinical Trials Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Omics-Based Clinical Trials Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Omics-Based Clinical Trials Market size was valued at USD 8.7 Billion in 2024 and is poised to grow from USD 9.81 Billion in 2025 to USD 25.72 Billion by 2033, growing at a CAGR of 12.8% during the forecast period (2026-2033).
The competitive landscape is shaped by major pharmaceutical groups and technology firms accelerating omics integration through strategic acquisitions, joint ventures, and platform enhancements; for example, a leading biotech acquired a genomics data analytics company to expand its trial design capabilities, while a cloud‑based health data provider partnered with a clinical research organization to embed multi‑omics biomarkers into protocol development, intensifying rivalry and driving innovation. 'IQVIA', 'Labcorp Drug Development', 'ICON plc', 'Parexel', 'Thermo Fisher Scientific', 'Syneos Health', 'Medpace', 'Charles River Laboratories', 'Eurofins Scientific', 'Tempus AI', 'Illumina', 'QIAGEN', 'SOPHiA GENETICS', 'Roche', 'Natera', 'Personalis', 'Bio-Rad Laboratories', 'DNAnexus', 'Veracyte', 'Guardant Health'
Precision Medicine Integration: The convergence of omics technologies with personalized therapeutic strategies is reshaping trial designs, enabling sponsors to stratify patient cohorts based on molecular signatures and to monitor treatment response with unprecedented granularity. This approach accelerates hypothesis testing, reduces attrition, and improves regulatory confidence, as adaptive protocols can be tailored in real time to emerging biomarker insights, fostering a more efficient pathway from early‑phase investigation to late‑stage confirmation and ultimately supporting differentiated product positioning in competitive therapeutic landscapes.
Why does North America Dominate the Global Omics-Based Clinical Trials Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
